Tenax soars after FDA clears heart failure drug for late-stage trial

Tenax Therapeutics

13/11/2023 15:38

** Shares of Tenax Therapeutics  TENX.O  rise as much as
169% to a near-three-month high of $0.42 in early trade; last up
152%
    ** Co says its drug for a type of heart failure has been
cleared by the FDA for late-stage trial
    ** TENX says it will start a late-study on the drug in Q4
    ** In the disease, patients with a type of heart failure
have increased blood pressure in the lungs' blood vessels
    ** No FDA-approved treatments for the disease, estimated
prevalence of more than 2 mln patients in North America by 2030
- co 
    ** Over 58.3 mln shares traded, more than 10x their 25-day
moving average
    ** Including session's gain, stock up 81.8% YTD

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))